The clinical-stage biopharmaceutical company is developing novel small-molecule drugs for cardiovascular and metabolic diseases, including diabetes, dyslipidemia, and cardiovascular disease. Their product portfolio includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver.